Novartis AG ADR (NVS)vsWarby Parker Inc (WRBY)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
WRBY
Warby Parker Inc
$22.53
-3.10%
HEALTHCARE · Cap: $2.63B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 6389% more annual revenue ($56.58B vs $871.90M). NVS leads profitability with a 23.9% profit margin vs 0.2%. NVS trades at a lower P/E of 21.2x. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
WRBY
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+30.9%
Fair Value
$31.81
Current Price
$22.53
$9.28 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
ROE of 0.5% — below average capital efficiency
0.2% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : WRBY
Revenue growth of 11.2% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : WRBY
The primary concerns for WRBY are EPS Growth, Return on Equity, Profit Margin. A P/E of 2147.0x leaves little room for execution misses. Thin 0.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS profiles as a declining stock while WRBY is a value play — different risk/reward profiles.
WRBY carries more volatility with a beta of 2.08 — expect wider price swings.
WRBY is growing revenue faster at 11.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 34/100), backed by strong 23.9% margins. WRBY offers better value entry with a 30.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Warby Parker Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Warby Parker Inc. is a pioneering force in the direct-to-consumer eyewear sector, established in 2010 to transform the optical experience through a combination of online convenience and an expanding network of retail locations. The company emphasizes stylish, affordable prescription eyewear and sunglasses, uniquely positioning itself to attract a diverse customer base. Its socially responsible business model, highlighted by the "Buy a Pair, Give a Pair" initiative, underscores a commitment to community welfare, providing eyewear to those in need. With a strong brand identity and innovative marketing approaches, Warby Parker is poised for sustained growth and resilience in an increasingly competitive industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?